Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth

Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth

Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Cetuximab, a human/mouse chimeric monoclonal antibody, is effective in a limited number of CRC patients because of cetuximab resistance. This study aimed to identify novel therapeutic targets in cetuximab-resistant CRC i...

Full description

Bibliographic Details
Main Authors: Mee Hyun Jeoung, Taek-Keun Kim, Ji Woong Kim, Yea Bin Cho, Hee Jun Na, Byong Chul Yoo, Hyunbo Shim, Dong-Keun Song, Kyun Heo, Sukmook Lee
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Biomolecules
Subjects:
cetuximab resistance
grp94
human antibody
colorectal cancer
Online Access:https://www.mdpi.com/2218-273X/9/11/681

Internet

https://www.mdpi.com/2218-273X/9/11/681

Similar Items